The novel serine protease PreR-Co promotes endothelium-independent vasorelaxation in rabbit aortic rings by Peral, Maria de Los Angeles et al.
The novel serine protease PreR-Co promotes endothelium-
independent vasorelaxation in rabbit aortic rings
MARI´A PERAL DE BRUNO,1 PAULA A. VINCENT,2 LILIANA ROMANO,1
D. CECILIA GUARDIA,2 ALFREDO COVIELLO,2 AND EDUARDO DE VITO2
1Departamento Biome´dico, Facultad de Medicina, and 2Instituto Superior de
Investigaciones Biolo´gicas, Consejo Nacional de Investigaciones Cientı´ficas y Te´cnicas,
Universidad Nacional de Tucuma´n, San Miguel de Tucuma´n 4000, Argentina
Submitted 6 September 2001; accepted in final form 24 September 2002
Peral de Bruno, Marı´a, Paula A. Vincent, Liliana
Romano, D. Cecilia Guardia, Alfredo Coviello, and
Eduardo De Vito. The novel serine protease PreR-Co pro-
motes endothelium-independent vasorelaxation in rabbit
aortic rings. Am J Physiol Heart Circ Physiol 284:
H704–H710, 2003. First published September 26, 2002;
10.1152/ajpheart.00792.2001.—The effect of a novel enzyme
(PreR-Co) that activates renal prorenin was studied on rabbit
aortas with and without endothelium. It was tested 1) in the
basal tone of nonstimulated or ANG II-sensitized rings or
rings precontracted with norepinephrine (NE), PGF2, high
KCl concentration, and 2) in rings pretreated with enalapri-
lat, losartan, PD-123319, N-nitro-L-arginine methyl ester,
HOE-140, indomethacin, or serine protease inhibitors (PMSF,
aprotinin, or soybean trypsin inhibitor); kallilkrein and brady-
kinin were also tested in ANG II-sensitized rings. PreR-Co
produced a vasorelaxant effect in the basal tone and in the
precontracted rabbit aorta. The effect was endothelium inde-
pendent, potentiated by endothelium removal or nitric oxide
(NO) synthase inhibition, and abolished by boiling the enzyme.
In addition, the effect improved when basal tone was increased
in ANG II-sensitized aortic rings or in precontracted vessels. No
activation of the ANG II, bradykinin, prostaglandin, or NO
pathway mediating the PreR-Co response could be obtained,
suggesting a direct action of the enzyme. This action seems to
be dependent on esterasic activity because serine protease
inhibitors like PMSF and aprotinin were able to block the
vasorelaxant effect of PreR-Co.
renin activators; vasorelaxant activity; rabbit aorta
THE RENIN-ANGIOTENSIN SYSTEM (RAS) has been involved
in the modulation of vascular tone. Its action is accom-
plished by a complex mechanism that involves interac-
tions with several systems in the circulation and in the
arterial wall (endothelium and smooth muscle). Local
endothelium relaxing factors like nitric oxide (NO),
prostacyclin, arachidonic acid vasodilator metabolites,
and EDHF and endothelium contractile factors like
endothelin, thromboxane A2, and PGH2 have been de-
scribed (8, 11, 20, 26, 35). The balance of these systems
as well as other factors are responsible for the regula-
tion of arterial vascular tone. The RAS interacts with
kallikrein-kinins through the converting enzyme kini-
nase II (19). Furthermore, demonstrations of all com-
ponents of the RAS have been reported in the arterial
wall (12, 17, 22, 27, 31), where ANG II stimulates
endothelial synthesis of prostaglandins and lipoxygen-
ase-derived eicosanoids (18) that modulate arterial
basal tone. In previous reports, we found that the basal
tone of the isolated rabbit aorta was dependent on
sensitization by ANG II (23) through activation of AT1
receptors (24).
As early as 1970, De Vito et al. (6) demonstrated that
active renin in rat kidney slices originated from an
inactive precursor (prorenin). Later on, a novel en-
zyme, named PreR-Co, which has a 65% homology with
kallikreins and 69% with serine proteases, was puri-
fied to a single electrophoretic band from rat plasma
(7). This enzyme activates in vitro inactive tissue
renins but not plasma prorenin (33). The presence of
considerable amounts of inactive renin in plasma and
tissues, which may be converted into relatively small
quantities of active renin, has opened the question of
its potential functions. Nevertheless, its physiological
significance remains unclear.
The objective of this paper was to study whether an
enzyme that converts prorenin into active renin in
vitro, PreR-Co, has any biological action in the isolated
rabbit aorta according to the following hypotheses: 1)
by activation of the tissue RAS, because this enzyme
activates tissue prorenin but not plasma prorenin; 2)
by activation of a kallikrein-kinin pathway, because
this enzyme has partial homology with kallikrein; and
3) by direct action. These observations were made in
the basal tone of nonstimulated or ANG II-sensitized
rabbit aortic rings (23–25) and also on hormonally
precontracted vascular smooth muscle.
MATERIALS AND METHODS
Purification of an Activating Renal Prorenin
Plasma Protein
Purification was performed on 24-h plasma from nephrec-
tomized rats as previously described (7, 34). In short, plasma
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was precipitated with (NH4)2SO4, followed by DEAE-cellu-
lose chromatography, gel filtration on Sephacryl S-200 HR,
immunoaffinity chromatography, and ion-exchange chroma-
tography using a MonoQ HR-5/5 column associated with a
fast-pressure liquid chromatography system and DEAE-
Sephadex AP-1 column associated with a high-pressure liq-
uid chromatography system. The active fraction capable of
activating inactive kidney renin, named PreR-Co, was dia-
lyzed against distilled water and stored in 50-l aliquots at
20°C. Aliquots were mixed in Krebs solution immediately
before the experiment. All the experiments on aortic rings
were made with a sample of PreR-Co that had been previ-
ously tested for its ability to convert prorenin in active renin.
Briefly, PreR-Co was tested in rat kidney extract incubated
with PreR-Co for 15 min at 37°C (34). The renin concentra-
tion was measured by incubation with homologous angio-
tensinogen and ANG I formed by radioimmunoassay. The
same protocol was repeated with samples activated by tryp-
sin (an enzyme that activates prorenin). The PreR-Co con-
centration used in isolated rabbit aortic rings experiments (1
g/ml) is 50 times lower than the appraised rat plasmatic
level (50 g/ml). Because at the present time there is no
available method to measure PreR-Co plasmatic levels, this
amount was obtained from the fact that a similar effect of
activation was obtained with 100 l of rat plasma as well as
with 5 g of enzyme. We point out that the assay was made
with rat kidney extract, as described above.
Rabbit Aorta Preparation
Thoracic aortas from male rabbits (Flanders hybrid, 1.5–2
kg body weight) were obtained from an authorized dealer.
The aorta, carefully cleaned of connective tissue, was im-
mersed in Krebs solution (in mmol/l: 128 NaCl, 4.7 KCl, 14.4
NaHCO3, 2.5 CaCl2, 1.2 NaH2PO4, 1.2 MgCl2, 0.1 Na2-
EDTA, and 11.1 glucose). Thereafter, the vessel was trans-
versely cut, yielding rings of 5-mm length. In some experi-
ments, the endothelium was removed by rubbing it with a
wire. The rings were fixed in a Lucite chamber to stainless
steel wire holders; one holder was anchored to the chamber,
whereas the other was attached to an isometric force trans-
ducer (Gould UC2) connected to a chart recorder (Kipp and
Zonnen BD 41). The chamber contained 7 ml of Krebs solu-
tion at 37°C, pH 7.2, and bubbled with 95% O2-5% CO2. In all
experiments, rings were equilibrated for 120 min pre-
stretched at a force of 2 g, which was previously found to be
the optimal tension for ANG II-induced contraction (23). The
experiment began when the baseline tension remained stable
while the bath solution was changed every 15 min. The
presence or absence of functional endothelium was tested, at
the end of the experiment, by assessing the ability of acetyl-
choline (106 mol/l) to relax the previously contracted aortic
rings with norepinephrine (NE). After this procedure, the
preparation was treated with 100 mmol/l KCl.
Protocols
Protocol 1: effect of PreR-Co on nonstimulated rabbit aortic
rings. To test the possible action of PreR-Co on the basal tone
of rabbit aortas that had not been exposed before to any
vasoactive agent (nonstimulated aortic rings), after a 1-h
equilibration period, aortic rings with and without endothe-
lium were treated with PreR-Co in a final bath concentration
of 1 g/ml, whereas the paired ring remained as a control.
Protocol 2: effect of ANG II sensitization in the response to
PreR-Co. In previous work (23), we demonstrated that sen-
sitization with ANG II induced a novel vasorelaxant action
on noncontracted smooth muscle to an endothelium-indepen-
dent agent like atrial natriuretic peptide (ANP). Therefore,
the objective of the design of the present protocol was to
investigate the possible effect of PreR-Co in ANG II-sensi-
tized rabbit aortic rings. Because the vasorelaxant effect of
ANP was found to be dependent of increased basal tone (23,
24), the present protocol was also performed to test a possible
potentiation in the response. Paired aortic rings with or
without endothelium were exposed to ANG II (1010–105
mol/l), obtaining a cumulative dose-response curve (CDRC).
The bath was changed each 15 min for 1 h until ANG II was
washed out and the baseline level was totally recovered. At
this time, PreR-Co (1g/ml) was added and the response was
followed for 7 min.
Protocol 3: effect of PreR-Co in precontracted rings. To test
the effect of PreR-Co in precontracted smooth muscle, rabbit
aortic rings with and without endothelium were exposed to
different agents. A NE CDRC (109–105 mol/l) was ob-
tained. Subsequently, after a stable plateau level was
reached, PreR-Co (1 g/ml) was added to one ring, with the
remaining paired ring as a control. The response to PreR-Co
in the contracted vessel was followed for 7 min. A similar
experiment was carried out using a different agonist, PGF2
(106 mol/l) or high KCl (100 mmol/l), as a contracting agent.
The role of endothelium in the response to PreR-Co was
further studied in NE-contracted aortas with endothelium
treated or not treated with an inhibitor of NO synthase,
N-nitro-L-arginine methyl ester (L-NAME; 104 mol/l). To
rule out the possible presence of a thermostable vasoactive
nonenzymatic compound, the enzyme was tested after it was
heated for up to 5 min in a boiling bath and added (1 g/ml)
to the NE-precontracted vessel.
Protocol 4: effect of inhibitors of the RAS and kinins in the
response to PreR-Co. To test the effect of inhibitors at differ-
ent levels of the RAS on the response to PreR-Co, different
compounds were used: an angiotensin-converting enzyme
(ACE) inhibitor (enalaprilat) with the purpose of blocking a
possible tissue generation of ANG II, and an inhibition of
local kinin degradation, because the converting enzyme also
has kininase II activity (19). Aortic rings with or without
endothelium were treated with ANG II to obtain a CDRC
(1010–105 mol/l). After the rings were washed and had
recovered to baseline levels (ANG II-sensitized aortas), 106
mol/l enalaprilat was added for 15 min to the aortic bath and
PreR-Co (1 g/ml) was added to both control and treated
rings. A similar experiment was carried out using nonpep-
tidic ANG II receptor antagonists: the AT1 antagonist losar-
tan (105 mol/l) and the AT2 receptor antagonist PD-123319
(1.36  105 mol/l). The objective of this study design was to
rule out any action of ANG II in mediating the aortic ring
response to PreR-Co.
To test any nonspecific activity of PreR-Co through the
release of a vasorelaxant agent related to kinins, a bradyki-
nin B2 receptor antagonist [107 mol/l D-Arg-(Hyp3,Thi5,D-
Tic7,Qic8)bradykinin (HOE-140)] was added to ANG II-sen-
sitized aortic rings as described above.
Protocol 5: effect of kallikrein and bradykinin on rabbit
aortic rings sensitized with ANG II. The hypothesis of a
tissular kalllikrein-bradykinin pathway effect in resting
basal tone of ANG-II sensitized aortic rings and the possible
effect of PreR-Co through its activation was tested using
agonists and antagonists of this system. Rabbit aortic rings
with or without endothelium were sensitized with ANG II (as
described in protocol 2) with the addition of kallikrein (1
g/ml). A similar experiment was run with bradykinin, and a
CDRC (1011–106 mol/l) was obtained in the presence or
absence of the B2 receptor antagonist HOE-140 (107 mol/l).
In rabbit aortic rings with endothelium, a CDRC to bradyki-
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nin (1011–106 mol/l) was also obtained during the plateau
of a contraction induced by NE (105 mol/l).
Protocol 6: effect of indomethacin on the response to PreR-
Co. To test whether some cyclooxygenase-derived metabolite
was mediating the vasorelaxant effect of PreR-Co, experi-
ments were performed with indomethacin (a cyclooxygenase
inhibitor). Paired rabbit ANG II-sensitized aortic rings with
endothelium were treated or not treated with indomethacin
(105 mol/l) for 15 min, and, thereafter, PreR-Co (1 g/ml)
was added. A similar protocol was carried out in NE-precon-
tracted vessels.
Protocol 7: effect of serine protease inhibitors on the re-
sponse to PreR-Co. Aortic rings with endothelium were
treated with different serine protease inhibitors: plasma [1
g/ml soybean trypsin inhibitor (SBTI)] and tissue kallikrein
inhibitors (1 g/ml aprotinin) or a nonspecific serine protease
inhibitor (1 g/ml PMSF). Each inhibitor was added for 15
min to the aortic bath to nonstimulated or ANG II-sensitized
aortic rings. Afterward, PreR-Co (1 g/ml) was added to both
the control and treated samples.
To rule out the possibility that inhibitors added to the bath
did not have enough time to inactivate the enzyme before
their interaction with the aortic tissue, another series of
experiments were performed. PreR-Co (100 g/ml) was incu-
bated for 15 min in Ringer solution (control) or with PMSF
(0.1 or 0.48 mg/ml), SBTI (0.1 or 1.0 mg/ml), or aprotinin (0.1
or 2.0 mg/ml), and, after that, 70 l of the incubating solution
were added to 7 ml of the bathing solution containing the
aortic ring (final concentration of PreR-Co was 1 g/ml). The
higher concentrations were selected because they have been
proved to be effective on prorenin activation (34). The lower
concentrations of inhibitors were in the range of those of
PreR-Co producing a vasorelaxant effect. Because the
PreR-Co vasorelaxant effect is greater in the precontracted
aortic ring, experiments with simultaneous incubation of
PreR-Co and inhibitors were performed by adding the en-
zyme at the plateau of a NE contraction.
Chemicals
Human ANG II, NE (DL-arterenol), acetylcholine bromide,
indomethacin, kallikrein, bradykinin, HOE-140, SBTI, phenyl-
methylsulfonyl fluoride (PMSF), and aprotinin were pur-
chased from Sigma Chemical (St. Louis, MO). Enalaprilat
(Lotrial) was from Roemmers. Losartan was a gift from Dr.
Ronald Smith (Merck). PD-123319 (P-186) was obtained from
Research Biochemicals (Natick, MA). L-NAME was a gift from
Dr. Alberto Nasjletti (New York Medical College, Valhalla, NY).
Analysis of Results
The results, expressed as means  SE, were analyzed by
Student’s t-test to compare paired and unpaired averages.
When more than two means were compared, ANOVA and the
Newman-Keuls test were used when appropriate. The statis-
tical program chosen was GraphPad Prism (GraphPad Soft-
ware, San Diego, CA), and the level of significance estab-
lished was P  0.05.
RESULTS
Figure 1 shows records of a typical experiment with
the relaxing effect of PreR-Co (1 g/ml) in rabbit aortic
rings without endothelium on the basal tone of a non-
ANG II-sensitized ring (A), on the basal tone of a
previously ANG II-sensitized ring (B), and on the pla-
teau of a NE-contracted ring (C). In all cases, the
tensions of aortic rings declined immediately in the
presence of PreR-Co. In aortic rings with endothelium,
the mean fall produced by PreR-Co on the basal tone of
nonstimulated rings was 101  44 mg (n 	 13),
whereas it was 327  105 mg (n 	 16) in ANG II-
sensitized rings and 1,916  561 mg (n 	 7) in the
NE-contracted rings. The effect was reversible be-
cause, after washout, the aortic ring recovered its con-
tractility to NE. In another experiment using a differ-
ent agonist (106 mol/l PGF2), a similar vasorelaxant
effect of PreR-Co was obtained in the precontracted
vessels.
When a sample of PreR-Co was placed for 5 min in a
boiling water bath, no relaxant effect in NE-precon-
tracted aortic rings with endothelium was observed
Fig. 1. Graphic recordings of a typical experiment showing the
response to PreR-Co (1 g/ml) of rabbit aortic rings without endo-
thelium. A: basal tone of a non-ANG II-sensitized ring; B: basal tone
of a sensitized ANG II sample; C: plateau of a norepinephrine
(NE)-contracted ring.
H706 VASORELAXANT EFFECT OF PRORENIN-ACTIVATING ENZYME
AJP-Heart Circ Physiol • VOL 284 • FEBRUARY 2003 • www.ajpheart.org
Downloaded from www.physiology.org/journal/ajpheart (200.082.100.228) on January 27, 2020.
(mean fall of 16  14 mg, n 	 5, in boiled samples vs.
1,038  250 mg, n 	 6, in nonboiled samples). No
significant difference in the contractile response to
high KCl in the absence or presence of PreR-Co was
obtained (developed tension of 4,952  880 mg, n 	 7,
and 4,489  860 mg, n 	 7, respectively).
Figure 2 shows the response of PreR-Co on aortic rings
with and without endothelium and sensitized or not sen-
sitized with ANG II. Sensitized aortic rings without en-
dothelium significantly increased the response to
PreR-Co when compared with those rings not sensitized
to ANG II (P  0.01). This potentiation could not be
obtained in the presence of endothelium. The role of
endothelium in the response to PreR-Co was further
studied in NE-contracted unrubbed aortas treated or not
treated with L-NAME (104 mol/l). The mean vasorelax-
ant effect of PreR-Co was 707  89 mg in untreated
aortas (n 	 5), whereas in the L-NAME-treated pair it
was 2,705  663 mg (n 	 7, P  0.03, unpaired t-test).
The effect of PreR-Co in the basal tone of ANG II-
sensitized aortic rings with endothelium was not signifi-
cantly modified by either pretreatment with the ACE
inhibitor enalaprilat or the AT1 receptor antagonist lo-
sartan. The mean fall with 1 g/ml PreR-Co of arteries
with endothelium pretreated with enalaprilat (106
mol/l) was 356  156 mg (n 	 6), not significant with
respect to the nontreated control (327  125 mg, n 	 16,
unpaired t-test). The absence of endothelium did not
modify the lack of response to the ACE inhibitor (data not
shown). Figure 3 shows that losartan (105 mol/l, an
ANG II AT1 receptor antagonist) was unable to modify
the vasorelaxant effect of PreR-Co (1 g/ml) on the basal
tone of ANG II-sensitized aortic rings both with and
without endothelium. Furthermore, the potentiation of
the PreR-Co vasorelaxant effect by the absence of endo-
thelium was also present in losartan-treated vessels (P
0.05). PD-123319 (1.36  105 mol/l, an ANG II AT2
receptor antagonist) was also unable to modify the va-
sorelaxant effect of PreR-Co (1 g/ml), which added dur-
ing the plateau of NE-contracted rings with endothelium.
Mean relaxation was 2,358 367 mg in the control rings
(n	 6) and 2,238 450 mg in the experimental samples
(n 	 4, not significant, unpaired t-test).
To test whether the PreR-Co relaxing effect is medi-
ated by kininogenasic activity releasing endogenous bra-
dykinin, kallikrein and bradykinin were tested in ANG
II-sensitized aortic rings. Kallikrein (1 g/ml) did not
show any effect on aortic rings. A CDRC for bradykinin
(1011–106 mol/l) showed only a contracting effect that
was obtained with concentrations over 109 mol/l, and no
difference was obtained in the absence of endothelium
(Fig. 4). The contractile effect of bradykinin in arteries
with endothelium was not modified by pretreatment with
HOE-140 (107 mol/l). In addition, no activity of brady-
kinin was obtained in NE-precontracted vessels. In an-
other series of experiments, no effect of HOE-140 (107
mol/l) was obtained in the vasorelaxant effect of PreR-Co
(1 g/ml) in ANG II-sensitized aortas with endothelium
(188  61 mg, n 	 5, in the control vs. 176  54 mg, n 	
5, with HOE-140, not significant, unpaired t-test). The
vasorelaxant activity of PreR-Co (1 g/ml) was not mod-
ified by pretreatment with indomethacin (105 mol/l) in
NE-precontracted rings with endothelium, as shown in
Fig. 5.The effect of PreR-Co (1 g/ml) on the basal tone in
ANG II-sensitized and nonsensitized aortic rings with
endothelium was not modified by pretreatment with
SBTI (1 g/ml), PMSF (1 g/ml), or aprotinin (1 g/ml).
The effect of PreR-Co on ANG II-sensitized arteries was
327  125 mg (n 	 16), which was not modified by
pretreatment with SBTI (337 153 mg, n	 5), aprotinin
(391  90 mg, n 	 5), and PMSF (261  150 mg, n 	 5)
(not significant, ANOVA post test with Newman-Keuls).
Similar results were obtained in nonstimulated aortic
rings (data not shown). The vasorelaxant effect of
Fig. 2. Effect of PreR-Co (1g/ml) on the basal tone of noncontracted
rabbit aortas with and without previous sensitization with ANG II. No
difference was found in the PreR-Co effect on rings with endothelium
(
E) vs. those without endothelium (E) in nonsensitized aortic rings,
whereas the effect was significant in ANG II-sensitized rings (**P 
0.01, paired Student’s t-test). No difference was found when comparing
the effect of PreR-Co on non-ANG II-sensitized rings vs. sensitized rings
with endothelium, whereas it was significant in the rings without
endothelium (

P 0.01, ANOVA and Newman-Keuls test). Means
SE are indicated; n, number of experiments. NS, not significant.
Fig. 3. The effect of losartan (105 mol/l) was proven in rabbit aortas
previously sensitized with ANG II. No significant difference was
found in the vasorelaxant action of PreR-Co (1 g/ml) on rings with
and without endothelium. No difference was found when comparing
the effect of PreR-Co on losartan-treated vs. nontreated rings (NS,
paired Student’s t-test). Means  SE are indicated.
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PreR-Co was inhibited when the enzyme was preincu-
bated with PMSF or aprotinin before being added to the
bath containing the aortic ring. This inhibition was dose
dependent (Fig. 6). However, SBTI, even in the highest
concentration, produced nonsignificant inhibition (Fig. 6).
DISCUSSION
The present results demonstrate for the first time
that 1) PreR-Co, an enzyme that converts inactive
prorenin in active renin, relaxes isolated aortic rabbit
smooth muscle; 2) this relaxation is improved when the
vascular basal tone is increased and the vessels are
precontracted; 3) the relaxing response is endothelium
independent and potentiated by the removal of endo-
thelium or inhibition of NO synthase; 4) the relaxing
response appears not to be mediated by any autacoid
pathway receptor, supporting the view of a direct ac-
tion of PreR-Co; 5) this dilator action was dependent on
esterase activity and blocked by the serine protease
inibitors PMSF and aprotinin; and 6) the concentration
of PreR-Co producing a vasorelaxant effect in aortic
rings is 50 times lower than that converting in vitro
rat prorenin into active renin.The vasorelaxant effect
in nonstimulated aortic basal tone is very small, but it
is greatly increased in previously ANG II-sensitized
rabbit aortas. This result is analogous to that previ-
ously demonstrated in our laboratory (23–25) with
ANP. In addition, the PreR-Co relaxing effect is largely
increased in NE- or PGF2-precontracted rings. Never-
theless, it is difficult at present to define the mecha-
nism by which PreR-Co promotes the vasorelaxant
action. The presence of a thermostable nonenzymatic
vasoactive compound associated with PreR-Co was dis-
counted by the fact that the vasorelaxant response was
abolished after the sample was placed for a few min-
utes in a boiling water bath. PreR-Co is a novel enzyme
whose biological actions are unknown. In an earlier
study from this laboratory, we demonstrated that
PreR-Co promotes the activation of tissular prorenin to
renin in vitro (7, 33) and, furthermore, that it does not
cleave active renin or angiotensinogen. The lack of a
constrictor effect of PreR-Co may also be due to low
availability of the enzyme substrate prorenin in the
rabbit aortic wall and the inability of PreR-Co to cleave
plasma prorenin compared with renal tissue prorenin
(7, 33). The extrarenal prorenins, aortic and plasma,
would be insensitive to the enzymatic action of PreR-
Co. Prorenin is a heterogeneous protein, mainly due to
variable glycosylation (14). Moreover, it is not entirely
proven that inactive renin in the kidney has an iden-
tical configuration as that in circulating plasma (34).
This concept could be extended to other fluids and
tissues, including the aorta (33). Neither ACE inhibi-
Fig. 4. The effect of bradykinin (BK; 1012–105 mol/l) was proven
by a cumulative dose-response curve (CDRC) in rabbit aortas with
endothelium previously sensitized with ANG II. Only a contractile
effect was obtained with higher concentrations, and no significant
difference was found between the CDRC with and without endothe-
lium (NS, ANOVA and Newman-Keuls test). Means  SE are indi-
cated; n 	 8.
Fig. 5. Graphic recording of a typical experiment showing the re-
sponse to PreR-Co (1 g/ml) in NE-precontracted rabbit aortic rings
with endothelium. Rings were not pretreated (A) or pretreated (B)
with indomethacin (105 mol/l). Both recordings show a vasorelax-
ation promoted by PreR-Co independent of the prostanoid inhibition.
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tors nor AT1 or AT2 receptor blockers inhibited the
vasorelaxant response to PreR-Co. This would indicate
the absence of a vasoconstrictor counterbalancing ef-
fect through the release of local ANG II, suggesting
that another mechanism independent of prorenin to
renin activation is involved. The hypothesis of a va-
sorelaxant effect through other peptides of the angio-
tensin family having vasodilator properties, like ANG-
(1–7) (1, 9), ANG IV (3, 4), and ANG-(3–7) (15), is a
tenuous explanation, because, although vasorelaxant
action has been demonstrated, their effects are endo-
thelium dependent and mediated by NO or bradykinin.
Furthermore, in rabbit aortic rings, ANG-(1–7) lacks
vasorelaxant activity, and it behaves as an AT1 recep-
tor antagonist of ANG II (21). Because PreR-Co also
has kininogenase activity and a 65% homology with
kallikreins (34), a different hypothesis was examined
to assess whether the vasorelaxant effect could be
mediated by kinins. However, this hypothesis was
ruled out because no relaxant or contracting effect was
observed when kallikrein was tested in the rabbit aorta
ring preparation, probably because there is not enough
local substrate available (kininogen). Furthermore,
bradykinin had no relaxing effects but only a contrac-
tile action in our ANG II-sensitized rabbit aortic rings,
a fact that is in agreement with a previous report (29)
in precontracted vessels. In addition, the available
data demonstrate that only B1 but not B2 receptors are
present in the rabbit aorta (30). Thus it was expected
that HOE-140 (a B2 receptor blocker) did not inhibit
either the bradykinin or PreR-Co response.
The possibility that NO or a vasorelaxant prostanoid
acts as a mediator of the effect of PreR-Co seems
unlikely because removal of endothelium, NO synthase
inhibition, or indomethacin treatment did not abolish
the vasorelaxant response. On the contrary, in aortic
rings without endothelium or L-NAME treatment, the
vasorelaxant effect of PreR-Co was potentiated. In ad-
dition, the rabbit aorta is considered a bioassay rela-
tively insensitive to prostacyclin (10, 13). The potenti-
ation by disruption of endothelium may result in an
increase of basal tone produced by the lack of a coun-
terregulatory endogenous vasodilator like NO (28). De-
spite the fact that several contractile and vasodilator
prostanoids have been described (18), most of them are
endothelium dependent. Nevertheless, it has been re-
cently reported that a prostanoid derivative from eico-
sapentaenoic acid may produce a vasorelaxant effect in
Wistar-Kyoto rat aortas without endothelium (8). This
possibility was ruled out because pretreatment with
indomethacin was unable to inhibit the PreR-Co ac-
tion. Recent reports (2, 16) have demonstrated that a
hyperpolarizing factor derived from the endothelium
regulate K
 channels in vascular smooth muscle (like
coronary arteries), producing their opening and a con-
sequent hyperpolarization that results in smooth mus-
cle relaxation. The present results show that PreR-Co
was devoid of any significant relaxing effect on high
KCl-contracted rabbit aortas. Therefore, we assume
that PreR-Co or its released metabolite has to produce
the relaxing effect from the existence of a minimum
level of resting transmembrane potential. However, in
the high KCl-contracted vessel, this potential disap-
pears because of the lack of outward diffusion of potas-
sium, secondary to the abolition of the outward/inward
concentration difference (5, 32).
All of the above findings appear to support the view
that the relaxing response to PreR-Co is not mediated
by any autacoid pathway receptor. In addition, the
mechanism of the vasorelaxant action of PreR-Co ap-
pears to be independent of the tissue prorenin conver-
sion or of any product from the RAS or kallikrein
system. The present results clearly show that effect of
PreR-Co seems to be associated with its esterasic ac-
tivity because it was abolished by pretreatment with
PMSF (a nonspecific serine protease inhibitor) and
aprotinin. It is interesting to point out that there is a
difference in the enzymatic activity according to the
plasma or tissular substrate. We pointed out above the
difference between plasma and renal prorenin (34). At
present, we do not know how the inhibitors act with
PreR-Co. The first hypothesis of an interaction of
serine protease inhibitors with the substrate may be
ruled out because PreR-Co was inactivated before its
exposure to the vascular tissue. Therefore, it is more
probable that the action of inhibitors may be due to an
interaction on the active site of the enzyme PreR-Co. In
any case, it is necessary to point out that the enzymatic
Fig. 6. Effect of inhibitors of serine proteases on the vasorelaxant
action of PreR-Co in NE-precontracted aortic rings without endothe-
lium. The bars represent the percent inhibition of the effect of
PreR-Co. PreR-Co (100 g/ml) was incubated with lower and higher
doses of soybean trypsin inhibitor (SBTI; 0.1 and 1 mg/ml), aprotinin
(0.1 and 0.48 mg/ml), or PMSF (0.1 and 2 mg/ml) before the addition
of the enzyme to the bath containing the aortic ring. The final
concentration of PreR-Co in the aortic bathing solution was 1 g/ml.
No significant inhibition of lower and higher doses of SBTI was found
on the vasorelaxant effect of PreR-Co. On the other hand, a signifi-
cant dose-dependent inhibition by PMSF and aprotinin was found
with higher doses (

P 0.01, ANOVA and Newman-Keuls test). A
significant difference was found when comparing the effect of lower
and higher doses of PMSF and aprotinin (**P  0.01, paired Stu-
dent’s t-test). Means  SE are indicated.
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activity is required for PreR-Co vasorelaxation. It is
appropriate to emphasize that the present results show
for the first time that an enzyme that activates renal
prorenin by an unknown esterase activity produces a
vasorelaxant effect in basal tone and precontracted
rabbit aortic rings. This finding invites speculation
that PreR-Co may have physiological action as a mod-
ulator of vascular smooth muscle tone. Because its
vasorelaxant effect is greater when the vascular tone is
increased, it may have a role in different forms of
hypertension characterized by elevated vascular basal
tone (18, 28). Clarification of the precise mechanism
requires further investigation.
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